Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon et al
- PMID: 32475834
- PMCID: PMC7704575
- DOI: 10.1136/annrheumdis-2020-217990
Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon et al
Keywords: epidemiology; hydroxychloroquine; lupus erythematosus, systemic.
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.Ann Rheum Dis. 2020 Oct;79(10):1386-1388. doi: 10.1136/annrheumdis-2020-217690. Epub 2020 May 7. Ann Rheum Dis. 2020. PMID: 32381561 Free PMC article. No abstract available.
-
Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.Ann Rheum Dis. 2021 Apr;80(4):e54. doi: 10.1136/annrheumdis-2020-217847. Epub 2020 May 31. Ann Rheum Dis. 2021. PMID: 32475831 No abstract available.
References
-
- Carbillon L Clinical course of coronavirus disease 2019 (COVID-19) in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine remains to be evaluated. doi:annrheumdis-2020-217847 - PubMed
-
- Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017;76:476–85. doi: 10.1136/annrheumdis-2016-209770 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
